Home    中文  
 
  • Search
  • lucene Search
  • Citation
  • Fig/Tab
  • Adv Search
Just Accepted  |  Current Issue  |  Archive  |  Featured Articles  |  Most Read  |  Most Download  |  Most Cited

Chinese Journal of Lung Diseases(Electronic Edition) ›› 2024, Vol. 17 ›› Issue (01): 63-67. doi: 10.3877/cma.j.issn.1674-6902.2024.01.012

• Original Article • Previous Articles    

Effects of vitamin D3 combined with Montelukast sodium on serum VEGF, TGF-β1 and lung function in patients with bronchial asthma

Jing Bao1,(), Xia Wu1, Yaping Tian1, Gang Yin2   

  1. 1. Department of Respiratory Medicine, the First Hospital of Qiqihaer, Qiqihaer 161000, China; Department of Respiratory Medicine, Public Security Hospital of Qiqihaer, Qiqihaer 161005, China
    2. Morals Office, the First Hospital of Qiqihaer, Qiqihaer 161000, China
  • Received:2023-07-11 Online:2024-02-25 Published:2024-03-20
  • Contact: Jing Bao

Abstract:

Objective

To analyze the effects of vitamin D3 combined with Montelukast sodium on vascular endothelial growth factor (VEGF) and transforming growth factor (TGF-β1) and lung function in the treatment of bronchial asthma.

Methods

A total of 69 patients with bronchial asthma admitted to our hospital from January 2020 to December 2022 were selected as subjects. Vitamin D3 combined with Montelukast sodium treated 32 cases as observation group, Montelukast sodium treated 37 cases as control group. The therapeutic effect, clinical symptoms, lung function parameters, immune function level, serum VEGF and TGF-β1 levels and adverse reactions were compared between the two groups.

Results

After treatment, 28 cases (87.50%) were effective in observation group and 25 cases (67.56%) in control group (P<0.05). The clinical symptoms of the two groups were relieved, the relief of wheezing (3.45±0.55) d, cough (5.87±1.32) d, chest tightness (4.55±1.07) d, dyspnea (1.38±0.25) d and wheezing (4.44±1.32) d in the observation group were lower than those in the control group (P<0.05). The levels of FVC, FEV1 and PEF in the two groups were higher than those before treatment, and FVC (4.56±1.23) L, FEV1 (2.98±0.53) L and PEF (3.97±1.98) L/min in the observation group were higher than those in the control group (P<0.05). The level of immune function in both groups was improved compared with that before treatment (P<0.05). CD3+ (69.75±4.87) %, CD4+ (45.13±3.56) % and CD4+ /CD8+ (1.78±0.56) in observation group were higher than those in control group, and CD8+ (25.32±2.58) % were lower than those in control group (P<0.05). The levels of VEGF and TGF-β1 in the two groups were lower than those before treatment, and the levels of VEGF (223.62±63.35) ng/L and TGF-β1 (364±66.65) ng/L in the observation group were lower than those in the control group (P<0.05).

Conclusion

Vitamin D3 combined with Montelukast sodium is effective in the treatment of bronchial asthma, which can shorten the clinical symptoms of patients with bronchial asthma, improve lung function, enhance immunity, and reduce the levels of VEGF and TGF-β1.

Key words: Bronchial asthma, Vitamin D3, Montelukast sodium, Lung function, Vascular endothelial growth factor, Transforming growth factor

京ICP 备07035254号-28
Copyright © Chinese Journal of Lung Diseases(Electronic Edition), All Rights Reserved.
Tel: 023-65425691 E-mail: xqcjld@163.com
Powered by Beijing Magtech Co. Ltd